As of Mar 04
| +0.04 / +1.16%|
The 2 analysts offering 12-month price forecasts for Corcept Therapeutics Inc have a median target of 2.75, with a high estimate of 3.00 and a low estimate of 2.50. The median estimate represents a -20.98% decrease from the last price of 3.48.
The current consensus among 2 polled investment analysts is to Hold stock in Corcept Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.